Literature Review on the Immunogenicity of Herpes Zoster Vaccines
Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines.
- Publisher
- Public Health Agency of Canada
- Resources
- 2
- Catalogue metadata updated
- 2019-04-25
Data overview
- Formats
- HTML
- File languages
- English, French